- Mechanism
- Induces apoptosis in white adipose tissue vasculature
- Typical research dose
- 0.43 mg/kg/day (primate studies)
- Route
- subcutaneous
- Half-life
- Unknown
- Legal status
- Research Only
Overview
Adipotide is an experimental proapoptotic peptidomimetic engineered to induce rapid weight loss by targeting the blood supply of white adipose tissue. This targeted fat-burning peptide works by binding to specific proteins on the surface of fat-supporting blood vessels, triggering cell death and starving the fat cells of nutrients. Research indicates that the Adipotide peptide holds significant potential for treating severe obesity and improving metabolic conditions like insulin resistance, though it remains strictly limited to preclinical studies.
Potential Benefits
- Targeted Fat Loss: Studies in rhesus macaques show the Adipotide peptide selectively destroys white adipose tissue without affecting lean muscle mass (Barnhart et al., 2011).
- Rapid Weight Reduction: Animal models demonstrate significant decreases in overall body weight and BMI within weeks of administration.
- Improved Insulin Sensitivity: By reducing visceral fat, the peptide has been shown to lower blood glucose levels and improve insulin resistance in obese subjects.
- Appetite Suppression: Research indicates a secondary effect of reduced food intake, likely due to metabolic shifts following fat cell apoptosis.
- Reversal of Diet-Induced Obesity: Preclinical trials highlight its ability to normalize weight and metabolic markers in subjects previously fed high-fat diets.
Side Effects
Common side effects:
- Mild dehydration and increased thirst
- Changes in urine volume and frequency
- Temporary fatigue during initial fat breakdown
- Injection site reactions such as redness or swelling
Rare or serious side effects:
- Reversible renal lesions and kidney toxicity
- Elevated blood urea nitrogen (BUN) levels
- Potential cardiovascular strain from rapid lipid release
Adipotide is not FDA-approved and is intended for research purposes only. Consult a qualified healthcare provider before use.
Mechanism of Action
Vascular targeting is the primary mechanism by which the Adipotide peptide induces weight loss. The peptide features a specific homing sequence that binds exclusively to prohibitin, a membrane protein uniquely expressed on the surface of endothelial cells within the blood vessels of white adipose tissue. Once bound, the peptide is internalized by these endothelial cells, ensuring that its effects are localized entirely to fat-supporting vasculature rather than healthy organs.
Mitochondrial disruption follows the internalization of the peptide, driven by its pro-apoptotic domain. This domain damages the mitochondrial membranes of the endothelial cells, triggering rapid apoptosis that destroys the blood vessels. Without a viable blood supply, the targeted fat cells are starved of oxygen and nutrients, leading to their death and subsequent reabsorption by the body.
Origin & History
Discovery and development of Adipotide originated at the MD Anderson Cancer Center, led by researchers investigating vascular zip codes. The team utilized in vivo phage display to map the vasculature of white fat, leading to the identification of prohibitin as a targetable receptor. This breakthrough allowed them to engineer a synthetic chimeric peptide capable of delivering a toxic payload specifically to fat tissue, which was successfully tested in non-human primates (Barnhart et al., 2011).
Regulatory status for Adipotide remains strictly limited to laboratory and preclinical research. The FDA has not approved the Adipotide peptide for human consumption, weight loss therapy, or clinical use due to unresolved safety concerns. Ongoing research continues to evaluate its safety profile, particularly regarding renal toxicity, and its potential as a future therapeutic for severe obesity.